DEA schedule
Is Vyvanse a controlled substance?
Vyvanse contains lisdexamfetamine. Federal schedule from the FDA NDC directory, checked against the DEA controlled substances list.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
Yes. Vyvanse (lisdexamfetamine) is a Schedule II controlled substance under the federal Controlled Substances Act. Matching DEA list entry: Lisdexamfetamine (Schedule II).
Run it in Rivvi
Which 2027 plans near you dropped or restricted Vyvanse?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Schedule check
| Source | What it lists |
|---|---|
| FDA NDC directory | 13 prescription listings from 1 labelers, all Schedule II |
| DEA controlled substances list | Lisdexamfetamine: Schedule II |
DEA list entry
| Substance | DEA code | Schedule | Narcotic | Other names | Match |
|---|---|---|---|---|---|
| Lisdexamfetamine | 1205 | II | No | Vyvanse | Listed by name |
Vyvanse NDC listings
| NDC | Product | Form | Strength | Labeler | DEA schedule |
|---|---|---|---|---|---|
| 59417-101 | Vyvanse | capsule | 10 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-102 | Vyvanse | capsule | 20 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-103 | Vyvanse | capsule | 30 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-104 | Vyvanse | capsule | 40 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-105 | Vyvanse | capsule | 50 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-106 | Vyvanse | capsule | 60 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-107 | Vyvanse | capsule | 70 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-115 | Vyvanse | tablet, chewable | 10 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-116 | Vyvanse | tablet, chewable | 20 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-117 | Vyvanse | tablet, chewable | 30 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-118 | Vyvanse | tablet, chewable | 40 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-119 | Vyvanse | tablet, chewable | 50 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
| 59417-120 | Vyvanse | tablet, chewable | 60 mg/1 | Takeda Pharmaceuticals America, Inc. | CII |
Questions
Is Vyvanse a controlled substance?
Yes. Vyvanse (lisdexamfetamine) is a Schedule II controlled substance under the federal Controlled Substances Act. Matching DEA list entry: Lisdexamfetamine (Schedule II).
Is Vyvanse a narcotic?
No. The DEA list does not mark lisdexamfetamine as a narcotic (NARC = N) and places it in Schedule II. Its FDA established pharmacologic class is Central Nervous System Stimulant.
What schedule is Vyvanse?
Vyvanse is Schedule II in the FDA NDC directory, which matches the DEA controlled substances list.
Does this page cover state schedules?
No. This page reports the federal schedule only. Some states schedule drugs on their own; check your state board of pharmacy.
More on Vyvanse
- What is Vyvanse used for?FDA label uses
- Generic for VyvanseFDA Orange Book
- What is Lisdexamfetamine used for?FDA label uses
- Is Lisdexamfetamine a controlled substance?Schedule II
- Generic for AryntaFDA Orange Book
- Central Nervous System Stimulants listFDA drug class
- NDC 59417-101Vyvanse NDC record
- NDC 59417-102Vyvanse NDC record
- NDC 59417-103Vyvanse NDC record
- Schedule II drugs listDEA schedule